Reinhard Dummer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (18)
Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.
Year:
2025
Purpose: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100–positive cells, in metastatic uveal melanoma. Experimental Design: HLA-A*02:01–positive patients with unresectable or metastatic uveal melanoma enrolled in three clinical trials (IMCgp100-01, IMCgp100-102, and IMCgp100-202) who received ≥1 dose of tebentafusp were included. Safety data were pooled to evaluate the profile, onset, and management of treatment-related adverse events (TRAE). Adverse events of special interest included cytokine release syndrome (CRS), acute skin reactions (ASR), and liver function test elevations. Primary prophylaxis with medications was not permitted. Results: Among 410 tebentafusp-treated patients, the most common TRAE were pyrexia (77%), pruritus (71%), and chills (53%). Most patients experienced CRS (88%), almost always mild (grade 1, 19%) to moderate (grade 2, 67%) in severity, with only 2% experiencing grade 3 ( n = 6) or 4 ( n = 1) CRS. Additionally, 92% had at least one ASR, primarily pruritus and rash, with 21% having a grade 3 event. Onset of CRS and ASR was within 1 to 2 days of infusion and generally reversible with standard interventions. Elevated liver function tests were generally mild and resolved without intervention. Most TRAE occurred following the first few infusions and diminished in frequency and severity with repeated dosing; no cumulative TRAE were detected. Discontinuations due to TRAE were rare (2%); there were no treatment-related deaths. Conclusions: TRAE were consistent with tebentafusp’s mechanism of action, mostly occurred during dose escalation, and were predictable, reversible, and manageable with appropriate surveillance and intervention.
Year:
2025
Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies ( N = 410). A, Weekly incidence of TRAE during the acute phase (1–12 weeks). B, Long-term incidence of TRAE in 3-month intervals up to 30 months, which can be broken down into acute (months 1–3), intermediate (months 4–12), and late phases (>12 months). *Rash, LFT, and MRAE are composite terms for a list of related AE of any grade (Supplementary Table S1).
Year:
2025
Frequency of AESI by maximum grade and kinetics of onset and resolution of AESI. A, Frequency of each AESI by grade. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410). B and C, Median time to ( A ) onset from the start of the first dose or ( B ) resolution from the start of AESI for CRS, ASR, and LFT elevations. The peak of each curve shows the proportion of patients who developed that AESI. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410).
Year:
2025
Landmark OS for corticosteroid use within the first 30 days of the first tebentafusp dose. Kaplan–Meier plot of inverse probability of treatment–weighted OS (ATE weights) by corticosteroid use within the first 30 days of the first tebentafusp dose, landmarked at day 30. HR (95% confidence interval), 1.09 (0.67–1.76). ATE, average treatment effects.
Year:
2025
S2: HPLC analysis of STO13881 and nNeocuproine showed overlapping profiles and confirmed STO13881 to be neocuproine (purchased from Sigma-Aldrich, Switzerland). High-performance liquid chromatography (HPLC) analysis was performed using the Zuürich functional genomic center.
Year:
2025
Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mutation as well as the ratio of neocuproine normalized to the MEKi response.
Year:
2025
In cutaneous T‐cell lymphoma (CTCL), chronic pruritus affects up to 94% of patients as a leading factor reducing quality of life (QoL). Traditional antipruritic medication does not show sufficient relief. Partly due to a lack of therapeutic options, pruritus is rarely assessed in a standardized manner within routine clinical practice. In this cross‐sectional, single‐institution study, we characterized CTCL‐associated pruritus including perception, dynamics, and modifying factors. QoL was evaluated with the Dermatology Life Quality Index (DLQI) and EORTC core quality of life questionnaire (QLQ‐C30). Patients with early‐stage Mycosis fungoides (MF, n = 16), late‐stage MF ( n = 10) and Sézary syndrome (SS, n = 10), treated at the University Hospital of Zurich, completed all three questionnaires. 80.5% ( n = 29/36) patients reported disease‐associated pruritus worsening with stress (51.7%, n = 15/29), scratching (37.9%, n = 11/29), and sweating or exercise (31.0%, n = 9/29). DLQI was associated with CTCL‐specific skin involvement (modified severity‐weighted assessment tool, mSWAT) (ρ = 0.44, p < 0.01), worst experienced pruritus ( ρ = 0.42, p = 0.04) and current perceived pruritus ( ρ = 0.60, p < 0.01). Summarizing those three factors in a Pruritus‐Score correlated strongly with DLQI ( ρ = 0.71, p < 0.01), QLQ‐C30 global health status ( ρ = −0.71, p < 0.01) as well as fatigue ( ρ = 0.50, p = 0.02). Our results confirm the relevance of pruritus in CTCL. The Pruritus‐Score outperforms solely assessment of present pruritus in identifying patients who might experience related impairments in QoL. It quantifies this complex symptom in three factors that can be collected in clinical practice. This Pruritus‐Score can support consideration of pharmaceutical and non‐pharmaceutical approaches aimed at addressing reductions in quality of life and associated symptoms such as fatigue.
Year:
2025
PFS in ( A ) part I/run-in and ( B ) part II. A, Kaplan–Meier analysis of PFS with encorafenib plus binimetinib in naïve and pretreated patients in the FAS population. B, Kaplan–Meier analysis of PFS in the encorafenib plus binimetinib and ribociclib, encorafenib plus binimetinib and capmatinib, and encorafenib plus binimetinib and buparlisib arms.
Year:
2025
Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study, assessed encorafenib plus binimetinib combined with a third targeted agent after tumor progression on encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. Patients and Methods: Adults with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma who were BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) treatment–naïve or pretreated received encorafenib plus binimetinib (part I/run-in). Based on the genomic testing at disease progression following encorafenib plus binimetinib, patients were assigned to one of four treatment arms to receive encorafenib plus binimetinib with an appropriate molecularly targeted agent (ribociclib, infigratinib, capmatinib, or buparlisib; part II). The primary endpoint was best overall response; safety, biomarkers, pharmacokinetics, and other efficacy endpoints were also assessed. Results: In part I/run-in, 75 BRAFi/MEKi-naïve patients and 83 BRAFi/MEKi-pretreated patients were treated; in part II, 58 patients were treated (ribociclib, n = 38; infigratinib, n = 1; capmatinib, n = 13; buparlisib, n = 6). The overall confirmed response rate was 73.3% [95% confidence interval (CI), 61.9–82.9] in BRAFi/MEKi-naïve patients, 25.3% (95% CI, 16.4–36.0) in pretreated patients, 2.6% (95% CI, 0.1–13.8) in the ribociclib arm, and 0% in the other three arms. Adverse events were manageable and consistent with the known safety profile of each drug. Conclusions: LOGIC 2 supports the use of encorafenib plus binimetinib for treatment-naïve and previously treated, locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. However, adding a third targeted agent following disease progression did not show meaningful efficacy; further research is needed to identify other therapeutic targets to circumvent resistance.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (61)
caroline robert
- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse
Université de Paris Faculté de Santé
Govind Warrier
Assistant Professor of Oncology
Johns Hopkins University
Georgina V. Long
University of Sydney
Pål Johansen
University of Zurich
Joseph J. Sacco
Senior Lecturer Clinical
University of Liverpool
Andrea Bileck
Senior Scientist
Universität Wien
Jessica C. Hassel
Heidelberg University
L. V. Maul
-
Takami Sato
Professor
Thomas Jefferson University
Mitchell Levesque
-
Ossia M Eichhoff
Senior Scientist
University Hospital of Zurich
Patricia Bortel
University Assistant
Universität Wien
Stefan Kasper
Professor of Medical Oncology
-
Verena Paulitschke
Assoc.Prof. Dr./ PhD
Medical University of Vienna
Alaa Othman
Metabolomics Unit Head
ETH Zurich
Christopher Gerner
Full Professor
-
Michael Krauthammer
Professor
University of Zurich
Alexander M. Menzies
University of Sydney
Anna Spreafico
University Health Network
Nicola Zamboni
Adj. Prof
ETH Zürich
Bartosz Chmielowski
Ronald Reagan UCLA Medical Center
Marcus Butler
University Health Network
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Wilson H Miller Jr
McGill University
Zsolt Balázs
Senior Researcher
University Hospital of Zurich
Cornelia Mauch
Assistant professor
university hospital of the ruhr university bochum
Anthony M. Joshua
Head of Department
University Health Network
Ignacio Melero
Kidani Professor of Cancer Immuno-Therapeutics
University of Oxford
Michael A. Postow
Weill Cornell Medical College
F. Dimitriou
Attending Physician, Head of Skin Cancer Center
University Hospital of Bern
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
Alexander Noor Shoushtari
Memorial Sloan Kettering Cancer Center
Christoph Hoeller
Associate Professor, Head of Skin Cancer Center
Medical University of Vienna
Paul Nathan
University College London
Lars French
Professor of Precision and Translational Dermatology
Ludwig-Maximilians-Universität München
Georg Stary
Attending, Group Leader
Medical University of Vienna
Ramon Staeger
University Hospital of Zurich
Berend Snijder
Assistant Professor
ETH Zürich
Ryan Sullivan
Harvard University
Sebastian Ochsenreither
Charité - Universitätsmedizin Berlin
Elena Garralda
Director
-
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Alexander Leitner
Senior Scientist / Principal Investigator
ETH Zürich
I. Steiner
-
Hubert Hackl
Associate Professor
Medical University of Innsbruck
Lucie Heinzerling
University Hospital
Shahneen Sandhu
-
Zlatko Trajanoski
Professor
Medical University of Innsbruck
Martin Schuler
Professor of Medicine
Universität Duisburg-Essen
Piotr Rutkowski
Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie
Ludovic Gillet
Lecturer
ETH Zürich
Martin Distel
Associate Professor
University of Utah
Mark Middleton
University of Oxford
Andreas Dominik Braun
Professor for Digital and Molecular Dermatopathology
University of Lübeck
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
Adelheid Elbe-Bürger
Lab head
Medical University of Vienna
Phil Cheng
Bioinformatician
University Hospital of Geneva
Shailender Bhatia
Fred Hutchinson Cancer Research Center
W. Weninger
Professor and Chair
Medical University of Vienna
Jason J. Luke
-
Ines Pires da Silva
Medical Oncologist
University of Sydney
Make your next move.
Prepare your application
Review drafts before you send them.